Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H34O4 |
| Molecular Weight | 350.4923 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 8 / 8 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@]12CC[C@H]3[C@@H](CC[C@H]4C[C@@H](O)CC[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO
InChI
InChIKey=UPTAPIKFKZGAGM-NWIHUDFTSA-N
InChI=1S/C21H34O4/c1-19-8-5-14(23)11-13(19)3-4-15-16(19)6-9-20(2)17(15)7-10-21(20,25)18(24)12-22/h13-17,22-23,25H,3-12H2,1-2H3/t13-,14-,15+,16-,17-,19-,20-,21-/m0/s1
Originator
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: http://www.google.ch/patents/US6245757
Rat: 4.0 mg/kg 30 minutes before Middle cerebral artery occlusion (MCAO). The remaining injections (all 4.0 mg/kg) were given at 6 and 24 hours after MCAO, respectively.
Route of Administration:
Intraperitoneal
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
B2U92ZJ86E
Created by
admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
|
PRIMARY | |||
|
m18
Created by
admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
|
PRIMARY | Merck Index | ||
|
20054822
Created by
admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
|
PRIMARY | |||
|
516-47-2
Created by
admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
|
PRIMARY | |||
|
DTXSID40965922
Created by
admin on Mon Mar 31 17:53:19 GMT 2025 , Edited by admin on Mon Mar 31 17:53:19 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD